business
breaking news As per Street estimates, Rs 4 Dividend declared
Sun Pharma, in the fourth quarter, posted profits in line with street estimates. Revenue jumped 16% year-on-year to Rs 10,931 crore against the CNBC-TV18 poll of Rs 11,109 crore.
Live
Earnings before interest, tax, depreciation and amortization (EBITDA) rose 20% year-on-year to Rs 2,803 crore from the CNBC-TV18 poll of Rs 2,781 crore. EBITDA margins improved by 80 bos to 25.6%, compared to estimates of 25%. The Big Pharma company’s net profit at Rs 1,985 crore is in line with estimates of Rs 1,949 crore.
The board has recommended a final dividend for the financial year 2022-23 of Rs 4 per share.
cnbctv18-forexlive-benzinga
Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
